Signadori Bio announced a €11.1 million seed‑extension round in May 2026.The financing brings new investor Taiho Ventures alongside existing backers Sofinnova Partners and Invivo Partners.
Signadori Bio, a pre‑clinical‑stage biopharmaceutical company headquartered in Paris, disclosed that it has closed a seed‑extension financing round totaling €11.1 million to accelerate its next‑generation immunotherapy platform for solid tumours [3][4]. The announcement was made public in May 2026, though the precise day was not specified in the released statements [3][4].
The round was led by Taiho Ventures, a venture‑capital arm associated with Japan’s Taiho Pharmaceutical, marking the firm’s first participation in Signadori Bio’s financing [4]. Existing investors Sofinnova Partners and Invivo Partners also contributed additional capital, expanding their commitment to the company’s development programme [3][4]. The funding is classified as a seed‑extension, indicating that it builds on a prior seed round while providing resources to move the immunotherapy candidate further toward clinical evaluation [3][4].
Funding Structure and Investor Participation
The €11.1 million seed extension was structured as equity investment in Signadori Bio SAS, the legal entity that operates the startup’s research activities [3][4]. Taiho Ventures contributed a portion of the new capital, reflecting its strategic interest in novel cancer‑immunotherapy approaches [4]. Sofinnova Partners, a European life‑science venture firm, reaffirmed its support by participating in the round, consistent with its portfolio focus on early‑stage biotech innovations [3]. Invivo Partners, a French investment fund specializing in health‑tech, also increased its stake, underscoring confidence in the platform’s scientific premise [3][4].
The financing round was executed through a private placement, with terms disclosed only to participating parties. No public debt instruments were involved, and the investors did not receive any government subsidies or grants as part of the transaction [3][4]. The capital will be allocated primarily to pre‑clinical studies, manufacturing scale‑up of the monocyte‑based therapeutic candidates, and regulatory preparation for an eventual IND (Investigational New Drug) filing [4].
Existing investors Sofinnova Partners and Invivo Partners also contributed additional capital, expanding their commitment to the company’s development programme [3][4].
Platform Technology and Development Milestones
French Biotech Startup Signadori Bio Secures €11.1 Million Seed Extension for Solid‑Tumour Immunotherapy
Signadori Bio’s platform centers on a monocyte‑derived cellular therapy designed to remodel the tumour microenvironment and enhance immune recognition of solid tumours [4]. The approach differs from conventional checkpoint inhibitors by targeting innate immune cells to deliver localized anti‑cancer activity [4]. Pre‑clinical data presented in the company’s May 2026 briefing indicated tumour regression in multiple murine models of pancreatic, colorectal, and lung cancer [4].
More than one-in-five CBSE Class 12 candidates applied for scanned answer sheets after the 2026 results, prompting a parliamentary briefing on the board’s digital marking…
The seed extension will fund the completion of GLP‑compliant toxicology studies required for regulatory submission, as well as the manufacturing of a GMP‑grade cell product for first‑in‑human trials [4]. Signadori Bio has outlined a timeline that targets an IND filing by the end of 2027, followed by a Phase 1/2 clinical trial in Europe and potentially the United States [4]. The company also plans to expand its scientific team, adding immunologists and process‑development engineers to meet the accelerated schedule [4].
Immediate Impact on Education, Research and Healthcare Stakeholders
The infusion of €11.1 million provides immediate resources for university laboratories and research institutes collaborating with Signadori Bio on immunotherapy studies [3][4]. Graduate students and postdoctoral fellows involved in the pre‑clinical work will gain access to additional funding for consumables, animal studies, and data‑analysis tools [3]. The partnership with Taiho Ventures may also open channels for knowledge exchange between French and Japanese research communities, potentially leading to joint publications and training opportunities [4].
For healthcare providers, the announced timeline suggests that novel therapeutic candidates could enter early clinical testing within two years, offering a prospective option for patients with hard‑to‑treat solid tumours [4]. Hospital oncology departments that engage in clinical trial networks may begin to evaluate trial participation agreements once the IND is filed, influencing patient enrollment pipelines [4]. Finally, the funding signals continued investor confidence in early‑stage biotech ventures in France, which could affect funding strategies of other French startups and the allocation decisions of venture capital firms focused on life sciences [3][4].
Key Facts
What: Signadori Bio secured €11.1 million in seed‑extension funding to advance its monocyte‑based immunotherapy platform for solid tumours.
Graduate students and postdoctoral fellows involved in the pre‑clinical work will gain access to additional funding for consumables, animal studies, and data‑analysis tools [3].
When: Announcement made in May 2026.
Impact: Funding accelerates pre‑clinical development, creates research opportunities, and sets a path toward clinical trials for new cancer treatments.
NewsNews
